ADXS-NEO: A new direction in Cancer Immunotherapy
ADXS-NEO: A new direction in Cancer Immunotherapy
Advaxis is pioneering a new direction in the war on cancer with a neo-epitope immunotherapy called ADXS-NEO.
WIth their ‘My Immunotherapy Neo-Epitopes’ (MINE) program, Advaxis is leading the charge in targeted immunotherapy.
Looking for an immunotherapy that provides a customized intelligent immune response? – Think MINE.
Immunotherapy News from China
- UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
- …Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to…
- UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
- …in Combination With Anti-PD-L1 Cancer Immunotherapy and …
- …Dosed in First-in-Human Clinical Study of Immunotherapy …
- JITC tumor and cancer immunotherapy papers collection
- Welcome to the submission|Journal for ImmunoTherapy of Cancer
- Immunotherapy shows promise for advanced lymphoma: study
- …from the Monotherapy Arm at the Phacilitate Immunotherapy …
- Allergy Immunotherapy Market to exceed US$ 3.33 Bn by 2025 …
Leave a Reply
You must be logged in to post a comment.